Literature DB >> 25175773

How immunoglobulin G antibodies kill target cells: revisiting an old paradigm.

Markus Biburger1, Anja Lux1, Falk Nimmerjahn2.   

Abstract

The capacity of immunoglobulin G (IgG) antibodies to eliminate virtually any target cell has resulted in the widespread introduction of cytotoxic antibodies into the clinic in settings of cancer therapy, autoimmunity, and transplantation, for example. More recently, it has become apparent that also the protection from viral infection via IgG antibodies may require cytotoxic effector functions, suggesting that antibody-dependent cellular cytotoxicity (ADCC) directed against malignant or virally infected cells is one of the most essential effector mechanisms triggered by IgG antibodies to protect the host. A detailed understanding of the underlying molecular and cellular pathways is critical, therefore, to make full use of this antibody effector function. Several studies over the last years have provided novel insights into the effector pathways and innate immune effector cells responsible for ADCC reactions. One of the most notable outcomes of many of these reports is that cells of the mononuclear phagocytic system rather than natural killer cells are critical for removal of IgG opsonized target cells in vivo.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ADCC; ADCP; Fc-receptor; Immunoglobulin G; Natural killer cell

Mesh:

Substances:

Year:  2014        PMID: 25175773     DOI: 10.1016/B978-0-12-800147-9.00003-0

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  13 in total

1.  A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.

Authors:  Amber Dunkel; Shixue Shen; Celia C LaBranche; David Montefiori; James P McGettigan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-05       Impact factor: 2.205

2.  Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells.

Authors:  Maria-Luisa del Rio; Carlos Fernandez-Renedo; Olivier Chaloin; Stefanie Scheu; Klaus Pfeffer; Yasushi Shintani; Jose-Antonio Perez-Simon; Pascal Schneider; Jose-Ignacio Rodriguez-Barbosa
Journal:  MAbs       Date:  2016-01-11       Impact factor: 5.857

3.  Untangling Fc and complement receptors to kill tumors.

Authors:  Cees E van der Poel; Michael C Carroll
Journal:  Nat Immunol       Date:  2017-07-19       Impact factor: 25.606

Review 4.  Beyond binding: antibody effector functions in infectious diseases.

Authors:  Lenette L Lu; Todd J Suscovich; Sarah M Fortune; Galit Alter
Journal:  Nat Rev Immunol       Date:  2017-10-24       Impact factor: 53.106

5.  IgG Glycome in Colorectal Cancer.

Authors:  Frano Vučković; Evropi Theodoratou; Kujtim Thaçi; Maria Timofeeva; Aleksandar Vojta; Jerko Štambuk; Maja Pučić-Baković; Pauline M Rudd; Lovorka Đerek; Dražen Servis; Annika Wennerström; Susan M Farrington; Markus Perola; Yurii Aulchenko; Malcolm G Dunlop; Harry Campbell; Gordan Lauc
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531

6.  Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice.

Authors:  Rens Braster; Simran Grewal; Remco Visser; Helga K Einarsdottir; Marjolein van Egmond; Gestur Vidarsson; Marijn Bögels
Journal:  PLoS One       Date:  2017-05-19       Impact factor: 3.240

7.  Afucosylated IgG Targets FcγRIV for Enhanced Tumor Therapy in Mice.

Authors:  Rens Braster; Marijn Bögels; Hreinn Benonisson; Manfred Wuhrer; Rosina Plomp; Arthur E H Bentlage; Rianne Korthouwer; Remco Visser; J Sjef Verbeek; Marjolein van Egmond; Gestur Vidarsson
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

Review 8.  Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy.

Authors:  Seung Hyun Kang; Chang-Han Lee
Journal:  Biotechnol Bioprocess Eng       Date:  2021-06-28       Impact factor: 2.836

9.  Forsythoside A Inhibits BVDV Replication via TRAF2-Dependent CD28-4-1BB Signaling in Bovine PBMCs.

Authors:  Quan-Jiang Song; Xiao-Gang Weng; Dong-Jie Cai; Wang Zhang; Jiu-Feng Wang
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

Review 10.  Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations.

Authors:  Souad Boune; Peisheng Hu; Alan L Epstein; Leslie A Khawli
Journal:  Antibodies (Basel)       Date:  2020-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.